Efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide in Black and Hispanic/Latine adults with HIV ‐1 initiating first‐line therapy: 5‐year follow‐up from two phase III studies
HIV Medicine · 2025
DOI: 10.1111/hiv.70018 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift HIV Medicine, 2025. Verfasst von C Martorell und 14 weiteren Autor:innen. Beteiligte Einrichtung: The Research Institute, Springfield, Massachusetts, USA. Hauptthemen laut MEDLINE: Adenine, Anti-HIV Agents, Emtricitabine, HIV Infections. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Gilead Sciences, Inc, Gilead Sciences.
Abstract (Originalsprache)
Introduction
Black and Hispanic/Latine people are disproportionately affected by HIV‐1 and may have a greater risk of comorbidities than non‐Black and non‐Hispanic/Latine people with HIV. However, they have historically been underrepresented in HIV clinical studies. We aimed to assess the efficacy and safety of first‐line antiretroviral therapy with bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) over 5 years in Black and Hispanic/Latine people with HIV.
Methods
We present two post hoc pooled analyses of participants who received B/F/TAF up to week 240 in studies 1489 (NCT02607930) and 1490 (NCT02607956). Outcomes were compared between self‐identified Black and non‐Black participants and between Hispanic/Latine and non‐Hispanic/Latine participants, including baseline characteristics, proportion with HIV‐1 RNA
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Research Institute, Springfield, Massachusetts, USA.
- Midway Immunology and Research Center, Fort Pierce, Florida, USA.
- Chatham CARE Center, Savannah, Georgia, USA.
- Triple O Research Institute, West Palm Beach, Florida, USA.
- Hospital Universitario La Paz, Madrid, Spain.
- North Texas Infectious Diseases Consultants, Dallas, Texas, USA.
ORCID-Profile: J T Hindman
Förderung
- Gilead Sciences, Inc
- Gilead Sciences
Zitieren
APA
Martorell, C., Ramgopal, M., Hagins, D., Osiyemi, O., Arribas, J. R., Berhe, M., Yazdanpanah, Y., Orkin, C., Santiago, L., Rosero, C., Unger, N., Liu, H., Rogers, R., Hindman, J. T., & Wurapa, A. (2025). Efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide in Black and Hispanic/Latine adults with HIV ‐1 initiating first‐line therapy: 5‐year follow‐up from two phase III studies. HIV Medicine. https://doi.org/10.1111/hiv.70018
Vancouver
Martorell C, Ramgopal M, Hagins D, Osiyemi O, Arribas JR, Berhe M, et al. Efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide in Black and Hispanic/Latine adults with HIV ‐1 initiating first‐line therapy: 5‐year follow‐up from two phase III studies. HIV Medicine. 2025. doi:10.1111/hiv.70018
BibTeX
@article{Martorell2025,
author = {Martorell, C and Ramgopal, M and Hagins, D and Osiyemi, O and Arribas, J R and Berhe, M and Yazdanpanah, Y and Orkin, C and Santiago, L and Rosero, C and Unger, N and Liu, H and Rogers, R and Hindman, J T and Wurapa, A},
title = {Efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide in Black and Hispanic/Latine adults with HIV ‐1 initiating first‐line therapy: 5‐year follow‐up from two phase III studies},
journal = {HIV Medicine},
year = {2025},
doi = {10.1111/hiv.70018}
}
EUVIMED